Peer-influenced content. Sources you trust. No registration required. This is HCN.
Annals of Internal Medicine
SEER registry analysis revealed striking birth cohort effects with appendiceal adenocarcinoma rates more than quadrupling in the 1985 birth cohort compared to the 1945 reference group.
Gastroenterology June 24th 2025
Dana-Farber Cancer Institute
Reed-Sternberg cells harbor chromosome 9p24 amplification encoding PD-1 ligand, creating therapeutic vulnerability exploited by checkpoint inhibitors with remarkable clinical responses.
Hematology/Oncology May 27th 2025
Oncology News Central (ONC)
Age bias in oncology can lead to younger patients receiving more aggressive treatments with marginal survival benefits, potentially compromising their quality of life.
Hematology/Oncology August 12th 2024
Hematology Advisor
In a recent phase 3 trial, a low-dose chemotherapy regimen demonstrated noninferior efficacy to standard-dose regimens in pediatric AML patients, while significantly reducing non-hematologic toxicities, an important consideration in pediatric oncology.
Hematology January 22nd 2024
Bridging the Gap: Twinning Programs Improve Pediatric Cancer Survival Rates Across Borders In a world where a few miles can determine the fate of a child with cancer, twinning programs are making a significant difference. These initiatives, which pair hospitals across borders, are helping to bridge the survival gap in pediatric acute leukemia between high-income and lower-income countries. Key Points: “There’s no pediatric centers in many of the mountain west states. If your kid gets cancer in Wyoming, you gotta go to Utah or Colorado or Mayo in Minnesota. But here, there’s really nice evidence that providing the right protocols, training, staff, and more, we could do this in more places and improve outcomes without developing a new drug.” Gwen Nichols, chief medical officer of the Leukemia and Lymphoma Society
Hematology/Oncology June 12th 2023
MDLinx
The first version of the test, launched in November 2022, assesses chromosomal copy number changes in blood, cerebrospinal fluid, and the aqueous humor of the eye to aid in the clinical diagnosis of patients with solid tumors, brain tumors, and retinoblastoma, respectively. The next version of the clinical assay, which will be available in about six months, will detect mutations and gene fusions.
Medical Oncology March 6th 2023